The Chemiluminescence Immunoassay (CLIA) analysers market in India is poised for significant growth, projected to achieve a robust compound annual growth rate (CAGR) of approximately 6% through the year 2033, according to a forecast by GlobalData.

These CLIA analysers, integral tools in the Indian medical landscape, offer a wide range of applications, including infectious disease testing and cancer biomarker analysis.

Despite accounting for only about 2% of the Asia-Pacific market in 2023, India's CLA analysers market is anticipated to expand substantially, playing a pivotal role in advancing healthcare delivery, disease management, and public health initiatives in the country.

A recent report by GlobalData titled "Immunochemistry Analyzers Market Forecast to 2033" emphasizes the importance of strategic initiatives for Indian diagnostic companies to strengthen their global foothold in the CLIA analyser segment. International collaborations are identified as a key strategy to enhance competitiveness and presence on a global scale.

In line with this, a notable collaboration has been established between Japan-based Fujirebio Inc and India-based Agappe Diagnostics.

The companies have entered into a contract development and manufacturing organization (CDMO) partnership for a cartridge-based CLIA system reagents manufacturing project, focusing on the immunology equipment Mispa i60 and Mispa i121. Under this agreement, Fujirebio will supply equipment and raw materials, while Agappe will develop and manufacture dedicated reagents adhering to regulatory standards.

Shreya Jain, a Medical Devices Analyst at GlobalData, highlights the significance of this collaboration, stating, "Despite the limitations including technology dependency, limited R&D investment, and market competition, India’s cost-effective manufacturing capabilities stemming from lower labor and operational expenses underscore its appeal as a manufacturing hub."

The collaboration aims to launch analysers and reagents in June 2024, with these products being marketed under Agappe's brand. This marks a significant milestone as Agappe becomes the first Indian company to offer a complete chemiluminescence solution with locally manufactured reagents.

Jain concludes by emphasizing the potential impact of chemiluminescence analysers on patient care and clinical outcomes across various medical domains. The advancements in technology, supportive regulatory frameworks, and strategic collaborations are seen as critical elements for realizing the full potential of CLIA analysers in India's evolving healthcare landscape.